https://orcid.org/0000-0003-0400-1951
Figures & data
Table 1. Monoclonal antibodies undergoing late-stage clinical studies or authorized for COVID-19*
Table 2. Antibody therapeutics granted first approvals in the European Union or the United States during 2020*
Figure 1. Number of antibody therapeutics first approved in the United States or European Union each year during 1997–2020*
*Data publicly available as of November 25, 2020. Red bars, first approvals for cancer. Blue bars, first approvals for non-cancer indications. Biosimilar antibody and Fc fusion protein products were excluded. A table of US and EU-approved antibody therapeutics is available at antibodysociety.org/resources/approved-antibodies/.
Table 3. Investigational antibody therapeutics in regulatory review in the European Union or the United States*
Table 4. Investigational monoclonal antibodies in late-stage clinical studies for non-cancer indications*
Table 5. Investigational monoclonal antibodies in late-stage clinical studies for cancer indications*
Figure 2. Global commercial clinical pipeline of monoclonal antibodies*
*Data publicly available as of November 15, 2020. Red bars, most advanced clinical study is in cancer. Blue bars, most advanced clinical study is in non-cancer indications. Approved or authorized mAb products, investigational mAbs in regulatory review, and all biosimilar antibodies and Fc fusion proteins were excluded. Phase 1/2 studies were included with Phase 2; pivotal or registrational Phase 2 and Phase 2/3 studies were included with Phase 3.
